MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze KYMR →
    • FindStock Picks / Stock Screener
    • Value · KYMRIntrinsic Value Calculator
    • Invest · KYMRInvestment Case
    • Hold · KYMR5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
KYMR stock logo

KYMR

Kymera Therapeutics, Inc.

$127.57
0.4
 (0.31%)
Exchange:  NASDAQ
Market Cap:  10.891B
Shares Outstanding:  84.39M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Nello Mainolfi
Full Time Employees:  273
Address: 
500 North Beacon Street
Watertown
MA
2472
US
Website:  https://www.kymeratx.com
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body’s inherent protein degradation system to selectively eliminate disease-causing proteins. The company’s pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
KYKYMR logoKYMRKymera Therapeutics, Inc.10.9B——-23.9%
BMBMRN logoBMRNBioMarin Pharmaceutical Inc.11.1B—13.7-1.0%
SMSMMT logoSMMTSummit Therapeutics Inc.11.3B——-145.8%
HAHALO logoHALOHalozyme Therapeutics, Inc.11.4B23.911.622.6%
TETECH logoTECHBio-Techne Corporation11.4B66.237.97.3%
PCPCVX logoPCVXVaxcyte, Inc.10.0B——-45.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/08/05 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue78,59247,07239,200
Gross Profit78,59247,07239,200
EBITDA-143,201-216,236-303,061
Operating Income-165,530-261,635-349,400
Net Income-146,962-223,858-311,400

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets575,759978,0351,742,812
Total Liabilities180,788142,416163,148
Total Stockholders Equity394,971835,6191,579,664
Total Debt84,67487,76182,252
Cash and Cash Equivalents109,966120,256357,011

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-102,826-194,501-232,891
Capital Expenditure-34,480-12,838-1,449
Free Cash Flow-137,306-207,339-234,340
Net Income-146,962-223,858-311,351
Net Change in Cash41,25210,273236,761

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)185,717.095Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)509,758.687Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)343,768.570Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-682,353.812Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-154,240.509Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-411,828.227Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-701,497.278Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)-173,383.975Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)-430,971.693Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)194,073.732Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)532,696.092Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)359,236.985Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)-5.110Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)-2.050Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-8.310Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)10Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)13Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
47.072M  ?P/S
 (TTM)
: 
106.54
?Net Income
 (TTM)
: 
-223.858M  ?P/E
 (TTM)
: 
-35.14
?Enterprise Value
 (TTM)
: 
10.594B  ?EV/FCF
 (TTM)
: 
-36.67
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-22.39%  ?ROIC
 (TTM)
: 
-23.94%
?Net Debt
 (TTM)
: 
-400.983M  ?Debt/Equity
 (TTM)
: 
0.05
?P/B
 (TTM)
: 
7.91  ?Current Ratio
 (TTM)
: 
11.13

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates KYMR intrinsic value between $16.15 – $16.15 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate KYMR Intrinsic Value

Common questions about KYMR valuation

Is Kymera Therapeutics, Inc. (KYMR) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Kymera Therapeutics, Inc. (KYMR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is KYMR a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether KYMR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is KYMR’s P/E ratio?

You can see KYMR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for KYMR?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is KYMR a good long-term investment?

Whether KYMR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Kymera Therapeutics, Inc.

  • Kymera Therapeutics, Inc. intrinsic value calculatorEstimate what the business is worth
  • Kymera Therapeutics, Inc. 5-year outlookWhat has to go right, and what could go wrong
KYMR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.31
MarketSnap

Trading Metrics:

Open: 126.93   Previous Close: 127.17
Day Low: 124.9   Day High: 129.72
Year Low: 36.65   Year High: 142.92
Price Avg 50: 116.92   Price Avg 200: 99.18
Volume: 808708   Average Volume: 774822

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
29-10-2026 14:28
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
Kymera Therapeutics Q3 Earnings Call Highlights
29-10-2026 14:15
Kymera Therapeutics Q3 Earnings Call Highlights
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
12-10-2026 09:30
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
04-09-2026 12:37
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
03-09-2026 12:50
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Kymera Therapeutics Q2 Earnings Call Highlights
05-08-2026 13:06
Kymera Therapeutics Q2 Earnings Call Highlights

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze KYMR →
    • FindStock Picks / Stock Screener
    • Value · KYMRIntrinsic Value Calculator
    • Invest · KYMRInvestment Case
    • Hold · KYMR5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.